STATUS OF URINARY 15-F2t-ISOPROSTANE LEVELS IN GENERALIZED TONIC–CLONIC SEIZURE PATIENTS WITH LEVETIRACETAM IN A TERTIARY CARE HOSPITAL

Objectives: The objective of the study was to analyze urinary 15-2t-isoprostane levels in epileptic patients with levetiracetam (LEV) and to compare the urinary 15-2t-isoprostane levels between the different age groups, smokers, and alcoholics. Methodology: The study was conducted in a tertiary care hospital. Urinary 15-2t-isoprostane levels were assayed in epileptic patients taking LEV. Twenty patients were recruited. Urinary levels of 15-F2t-isoprostane determined by ELISA. The patient’s age, gender, height, weight, smoking, and alcoholic history were collected using pro forma. Statistical analysis of data was performed using SPSS version 23.0. Results: A total of 20 participants recruited for the study. Among these, 70% were male and 30% were female. The mean weight and height were more in males compared to females. The mean 15-F2t-isoprostane level was significantly higher in males compared to females. More than 40% of the participants were in the age group of >40 years. However, the mean urinary 15-F2t-isoprostane level is higher in the age group of 19–30 years. Only 20% of the participants were smokers and alcoholics. Non-smokers and non-alcoholics had higher urinary 15-F2t-isoprostane levels compared to smokers and alcoholics. Conclusion: The urinary 15-F2t-isoprostane levels were more in males, the age group of 19–30 years, non-smokers and non-alcoholics. However, the levels are lesser when compared to earlier meta-analysis study. This concludes that LEV may have antioxidant effect. There is a need for further studies with more sample size and correlation of LEV and urinary 15-F2t-isoprostane levels.